Prescription opioid epidemic in Pennsylvania: lessons from Medicare and MedicaidLobo, Carroline (2018) Prescription opioid epidemic in Pennsylvania: lessons from Medicare and Medicaid. Doctoral Dissertation, University of Pittsburgh. (Unpublished)
AbstractThis dissertation seeks to provide evidence for interventions that large health systems can utilize to help mitigate the prescription opioid epidemic in Pennsylvania. Chapter one introduces the research problem. Chapter three examines the associations between physician prescribing specialties and opioid-related outcomes of opioid-use disorder (OUD), misuse, and overdose. Little is known about the variations in risk of OUD, misuse, and overdose by type of opioid prescribing specialties. Using data from Pennsylvania Medicaid, we examine the associations between the index and dominant opioid prescribing specialty and OUD, misuse, and overdose. We observe that Medicaid enrollees who receive their index opioid prescription or a majority of their prescriptions from specialties that treat chronic pain -pain medicine and physical medicine and rehabilitation- are at higher risk for OUD and misuse compared to primary care. Chapter four examines the associations between adherence to antidepressant medications among individuals with mood disorders and opioid use. Literature shows that antidepressants have anti-nociceptive effects in mitigating pain among individuals with mood disorders. Using Pennsylvania Medicaid data, we examine whether adherence to antidepressants among individuals with major depressive disorders (MDD) or anxiety disorders is associated with reduced opioid use. We observe that enrollees with MDD and no cancer, who achieve ≥ 20% adherence have significantly lower hazards ratios for opioid use than those who achieve <20% adherence. This dissertation has important implications for public health. Our findings provide evidence for interventions that health-systems can use to: (i) identify high-risk beneficiaries who use opioids, (ii) support evidence-based prescribing in settings where patients are at an elevated risk for adverse outcomes of opioid use, and (iii) increase adherence to antidepressant medications among individuals with MDD. Share
Details
MetricsMonthly Views for the past 3 yearsPlum AnalyticsActions (login required)
|